Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02346240 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 3
- Development phase
- 559
- Enrollment target
NCT02346240 is a Phase 3 study that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 559 participants.
The verdict
NCT02346240, a Phase 3 study, has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 559 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
Interventions
- OTHER Placebo
- BIOLOGICAL Etanercept
- BIOLOGICAL Certolizumab Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 559 participants |
| Start Date | 2015-02-11 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346240
The ClinicalTrials.gov registry entry for NCT02346240 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 559 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02346240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02346240 about?
NCT02346240 is a clinical study titled "Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)". The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT02346240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 559 participants. The study started on 2015-02-11. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT02346240?
The interventions under investigation include: Placebo (OTHER), Etanercept (BIOLOGICAL), Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02346240?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.